| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 153 |
| 1 | NIVOLUMAB | 121 |
| 2 | IPILIMUMAB | 57 |
| 3 | CARBOPLATIN | 20 |
| 4 | DURVALUMAB | 19 |
| 5 | LENVATINIB | 18 |
| 6 | PACLITAXEL | 12 |
| 7 | PACLITAXEL (AIBUMIN-BOUND) | 12 |
| 8 | CISPLATIN | 11 |
| 9 | OXALIPLATIN | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FENBENDAZOLE | 1 | 0.0093 |
| 1 | NIVOLUMAB AND RELATLIMAB-RMBW | 3 | 0.0058 |
| 2 | PEMBROLIZUMAB | 153 | 0.0014 |
| 3 | TREMELIMUMAB | 6 | 0.0014 |
| 4 | POTASSIUM IODIDE | 2 | 0.0013 |
| 5 | IPILIMUMAB | 57 | 0.0013 |
| 6 | NIVOLUMAB | 121 | 0.0012 |
| 7 | ENFORTUMAB VEDOTIN | 8 | 0.0010 |
| 8 | DURVALUMAB | 19 | 0.0009 |
| 9 | VONOPRAZAN FUMARATE | 6 | 0.0007 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Activation Gene-3 Blocker [EPC] | 3 | 0.0058 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 63 | 0.0013 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 124 | 0.0013 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 19 | 0.0009 |
| 4 | Platinum-based Drug [EPC] | 41 | 0.0001 |
| 5 | Human Immunoglobulin G [EPC] | 3 | 0.0001 |
| 6 | Bile Acid [EPC] | 3 | 0.0001 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 8 | Glinide [EPC] | 1 | 0.0001 |
| 9 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 2 | 0.0001 |